Navigation Links
Malignant in Biological Technology

Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research

... doors to patients diagnosed with both benign and malignant brain tumors. In a move that further establishes ... in the treatment of both benign and malignant brain tumors," said Marc Mayberg, M.D., ... and innovative treatments for both benign and malignant brain tumors. CABTT's unique design places its ...

Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA

... significant efficacy in patients with malignant mesothelioma that failed prior chemotherapy." ... and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE ... III clinical trials of ONCONASE in unresectable malignant mesothelioma and, in addition to ongoing efforts ...

Swedish Neuroscience Institute and Institute for Systems Biology in Seattle Form Alliance to Learn More about Brain Diseases

... serious diseases affecting the brain, such as malignant brain tumors," said Dr. Foltz. "Also of ... research into slowing or stopping the growth of malignant brain tumors. "One thing that's made learning ... disease and tremors; brain tumors (including both malignant tumors and benign tumors such as meningiomas); ...

Cellectar, Inc. Begins GMP Production

... the ability to carry the potent isotope inside malignant cells and destroy them without adversely ... radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of ... on their accumulation and selective retention in malignant tumors and not in normal cells. The company's ...

FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions

... the kidney. Detection and characterization of malignant and benign focal liver lesions with EOVIST may ... our ability to evaluate patients with benign and malignant focal hepatic lesions will be improved." The ... lesion characterization (i.e., distinction of malignant and benign types of liver lesions). EOVIST ...

Cellectar, Inc. Raises $13 Million in Private Offering

... radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of ... on their selective accumulation and retention in malignant tumors and not normal cells. The company's ... that this compound is selectively retained in malignant cells. In pre-clinical studies, CLR1404 was taken ...

Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB

... of cancer, since the receptor is crucial for the survival and growth of malignant cells. In contrast, the IGF-1 receptor is not absolutely necessary for ... for a wide range of human cancers such as breast cancer, prostate cancer, malignant melanoma, multiple myeloma, glioblastoma and sarcoma. AXL1717, orally ...

Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma

... determined by progression-free survival in patients with locally advanced malignant pleural mesothelioma. Secondary objectives include safety and anti-tumor ... rate. The patient population includes individuals with locally advanced malignant pleural mesothelioma who have not received any prior treatment for their ...

Alfacell Provides ONCONASE(R) NDA Submission Update

... rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. At the pre-NDA meeting, the FDA provided ... granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted ...

Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study

... and that late-stage clinical trials are justified." Sarcomas are malignant tumors growing from connective tissues, such as cartilage, fat, muscle, or ... These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma. ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

... of inhibiting the growth and causing apoptosis (programmed cell death) of malignant cells. Previously, ONCONASE has been shown to affect multiple cellular ... granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted ...

Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference

... dense breast tissue, found that CTLM could successfully distinguish malignant from benign lesions in dense breasts. The system's imaging capabilities ... density in breasts and could provide information about angiogenesis in malignant and benign breast lesions. Women who were scheduled for biopsy ...

Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors

... ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The Company's operations are based in ...

Alfacell Hires Advisors to Advance Strategic Alternatives

... granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted ... has completed Phase III clinical trials of ONCONASE in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related ...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

... for pursuing a U.S. approval for ONCONASE as a second-line treatment for malignant mesothelioma." Conference Call & Webcast Alfacell will host a ... granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted ...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

... highlighted in oral presentation at conference on malignant lymphoma LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II ...

Oncolytics Biotech Inc. Announces 2008 First Quarter Results

... to enroll patients in our Phase II sarcoma and in our Phase I/II recurrent malignant glioma clinical trials. Clinical Trials - Expanded Enrollment During ... These include patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma. ...

Alfacell Announces Retirement of Chief Executive Officer

... receiving marketing approval by the FDA of ONCONASE for the treatment of malignant mesothelioma, a significant stock option grant that vests upon such FDA ... and other life-threatening diseases. In addition to a Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in ...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008

... trial for ONCONASE (ranpirnase) in patients suffering from unresectable malignant mesothelioma. The company plans to begin the required statistical analysis ... life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in ...

FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma

... was also filed with the EMEA in Europe in the fall of 2007. About malignant Melanoma Approximately 60,000 people worldwide die each year from skin ... for the treatment of adult patients with chronic hepatitis C. In the malignant melanoma trial and other clinical studies, patients receiving ...

Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories

... candidate, is currently being evaluated as a treatment for unresectable malignant mesothelioma (UMM) in a confirmatory Phase IIIb clinical trial. "SPL has ... life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in ...

International team identifies 480 genes that control human cell division

... those genes that have an abnormal pattern of activation in cancer cells. malignant cells have lost control of the replication process, so detecting differences in cell cycle gene activation in normal and malignant cells provides important clues about how cancers develop, said Ziv ...

JCI table of contents: Dec. 3, 2007

... Notch-3 and led the authors to conclude that, IL-6 is a potent promoter of malignant features in Notch-3expressing normal and tumor stem/progenitor cells of ... IL-6 expression in primary lung adenocarcinomas. TITLE: IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal ...

Sanofi-aventis Announces Second Quarter 2009 Results

... A license agreement has been signed with Exelixis, along with an exclusive research collaboration to discover PI3K inhibitors in the treatment of malignant tumors. We have also entered into a collaboration agreement with Kyowa Kirin. Exploring external growth opportunities - In July, our Vaccines ...

NeoGenomics Reports Second Quarter 2009 Results

... and Europe have demonstrated that a very specific FISH panel test containing the genes and IP covered by our agreement with Abbott can distinguish malignant melanoma from pre-malignant or dysplastic nevi with a sensitivity of approximately 87-90% and a specificity of approximately 95%. Over the next six ...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

... is based on proprietary discoveries concerning the importance of stromal factors uniquely present within the surrounding microenvironment of malignant tumors. About Morphotek Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, is a biopharmaceutical company ...

Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting

... The investigators concluded that the data supports the use of reovirus in combination with standard radiation and chemotherapies for the treatment of malignant glioma in humans. The poster will be available on the Oncolytics website at www.oncolyticsbiotech.com at a later date. About Oncolytics ...

EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours

... EndoHPB can be used to ablate the occluding tissue. "The EndoHPB significantly improves on the procedure for patients suffering from malignant biliary obstruction," stated EMcision's CEO, the internationally renowned surgeon, Professor Nagy Habib. "I am particularly excited about ...

First Catalog Cancer Biochip for Sequence Capture Now Available from febit

... Eckart Meese, director of the Department of Human Molecular Genetics at Saarland University. "It is of utmost importance for our research on malignant brain cancer to obtain deep sequencing results of the 100 most relevant genes with high sequence coverage using the HybSelect technique. It is ...

New MRI technique could mean fewer breast biopsies in high-risk women

... a biopsy of a questionable lump or lesion. The universal technology will give radiologists greater confidence in visually classifying a lesion as malignant or benign. The American Cancer Society recommends that women with certain breast cancer risk factors including inherited genetic mutations, ...

CEL-SCI Files Patent Application to Support Company's Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses

... to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. ...

CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology

... to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. Each L.E.A.P.S. ...

Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial

... the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and ...

Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting

... IMPORTANT WARNINGS and PRECAUTIONS: increased mortality in elderly patients with dementia-related psychosis; QT prolongation; neuroleptic malignant syndrome; tardive dyskinesia; hyperglycemia and diabetes mellitus; weight gain; seizures; orthostatic hypotension and syncope; leukopenia, ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... prior chemotherapy. ALIMTA is not indicated for patients who have a different type of NSCLC called squamous cell. ALIMTA is a treatment for malignant pleural mesothelioma (MPM), which is a cancer that affects the inside lining of the chest cavity. ALIMTA is given with cisplatin, another anticancer ...

Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study

... their physician to be unresponsive to or untreatable by standard therapies. These included patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma. About Oncolytics Biotech Inc. Oncolytics is a Calgary-based ...

BD and Fujirebio Diagnostics Sign Worldwide Agreement to Develop Biomarker Assays to Improve Cancer Detection and Management

... higher sensitivity and specificity than CA125 alone. Improved sensitivity and specificity should allow clinicians to distinguish between benign and malignant pelvic masses more accurately, helping to ensure that patients receive appropriate therapy earlier. About Fujirebio Diagnostics, Inc. ...

CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies

... to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. The concept ...

CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease

... to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology. The concept ...

Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells

... produced by the P53 gene is activated to either coordinate the repair process in cells or induce cell suicide. Loss of normal p53 function results in malignant cell growth and has been linked to resistance to radiotherapy and chemotherapy in a number of cancers. In earlier work using animal models, Dr. ...
Other Contents
(Date:8/20/2014)... George E. Fox, a John and Rebecca Moores Professor ... was named a fellow in the International Society for the ... is one of four members two from the U.S., ... fellows in 2014. Fellows are elected every three years, and ... members from more than 20 countries, the ISSOL includes researchers ...
(Date:8/20/2014)... research finds life can persist in a cold, dark ... a team that examined waters and sediments from a ... found the extreme environment supports microbial ecosystems. , ... her colleagues has implications for life in other extreme ... The findings are published in the current edition of ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
(Date:8/21/2014)... Living in a quality residential community means enjoying ... it. A quality Home Owners Association like the one ... , Simpson Mill Plantation, a ... Management, LLC made a recent investment in a quality ... additional amenity for their neighborhood. , Situated near a ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Recently, ... among their patients. Alternative medicine is on the ... to millenials. According to The Fiscal Times, young ... treatments over conventional medicine. , The Fiscal Times ... many millenials are embracing alternative medicine. The article ...
(Date:8/21/2014)... arteries of chronic kidney disease patients may be a ... new study in the Journal of the American ... the Johns Hopkins Bloomberg School of Public Health assert ... of subclinical atherosclerosis in predicting the risk of heart ... percent of all patients with chronic kidney disease (CKD) ...
(Date:8/21/2014)... Patients with advanced laryngeal cancer appear to have ... than nonsurgical chemoradiation. , Author: Uchechukwu C. Megwalu, ... at Mount Sinai, New York, and colleagues. , ... cancer are diagnosed each year and squamous cell ... tumors. Prior to 1991, total surgical removal of ...
(Date:8/21/2014)... Improv performers from Fun House Theatre ... at Silverado Turtle Creek memory care community in Dallas. ... ranging from ages 10 to 16, delivers a groundbreaking ... set. The troupe's philosophy is that improv is based ... to touch audiences regardless of their circumstance — including ...
Breaking Medicine News(10 mins):Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 2Health News:Recreation is the Heart of the Community at Simpson Mill Plantation; Chooses American Parks Company™ for New Playground Equipment 3Health News:Van Uden Center Sees Growth in Alternative Medicine 2Health News:Measuring calcium buildup to predict heart disease in those with chronic kidney disease 2Health News:Surgery associated with better survival for patients with advanced laryngeal cancer 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2
Other TagsOther Tags